Recently, the list of units for Innovative Tasks for AI Medical Devices was announced. Big Vision Medical Technology was selected as one of the units for intelligent diagnostic products based on its independently developed ophthalmic OCT image-assisted diagnostic software (MIAS-3000).
In order to implement the important instructions and spirits of the state about promoting innovative tasks for AI medical devices, accelerate the deep integration development between AI technology and medical equipment, better serve and protect people’s health, on October 26, 2022, the General Office of the Ministry of Industry and Information Technology, Comprehensive and Planning Finance Department of the National Medical Products Administration announced the “Innovative Tasks for AI Medical Devices” list of units.
This task is aimed at intelligent products and supporting environments, focusing on eight categories of tasks: intelligent diagnostic products, intelligent auxiliary treatment products, medical AI databases, etc. The purpose is to collect and select a group of units with strong innovation capabilities to concentrate on tackling the difficulties and promote the innovative development of AI medical devices, accelerating the application of new technologies and products.
Big Vision Medical Technology
Big Vision Medical Technology is a high-tech enterprise founded by national talents. The company focuses on research and development, production, and sales of hardware and software systems for ophthalmic image artificial intelligence analysis and diagnosis. Its technology research and development capabilities are among the world’s leading, dedicated to creating a global leader in ophthalmic artificial intelligence. Currently, it has obtained more than 80 innovative achievements and patents, and has won awards such as the first prize of the “Wu Wenjun Artificial Intelligence Technology Invention Award” and the second prize of the “Jiangsu Provincial Science and Technology Award”, the highest award in the field of AI.
As an innovative enterprise deeply engaged in ophthalmic AI, Big Vision took a differentiated path from the beginning. Currently, most ophthalmic AI products on the market are based on fundus color images for diabetic retinopathy auxiliary diagnosis. While developing diabetic retinopathy AI, Big Vision Medical Technology was the first to conduct AI research on ophthalmic OCT images and has developed mature products in this area.
Ophthalmic Image Storage, Processing and Analysis System (MIAS)
In 2018, Big Vision Medical Technology released the industry’s first dual-mode ophthalmic image AI-assisted diagnostic system MIAS. Currently, it has initiated the detection and certification work for three types of medical device registration certificates. MIAS3000 is expected to become the world’s first OCT ophthalmic image-aided diagnostic system with a Class III medical device registration certificate.
Advanced multi-modal ophthalmic image AI algorithms can process and analyze ophthalmic optical coherence tomography (OCT) and fundus color images. High-precision image detection algorithms can identify pixel-level lesion areas and automatically mark minute lesions.
Professional:
It is the technical crystallization of multiple invention patents held by Big Vision and seamlessly integrated with hardware equipment. It provides a systematic solution for the large-scale screening and management of diabetic retinopathy, age-related macular degeneration, and other fundus diseases.
Intelligent:
It integrates advanced ophthalmic artificial intelligence algorithm models to automatically calculate the measured values of various indicators of the retina and fundus structure, accurately identify, segment, and automatically mark lesion areas.
Efficient:
It provides doctors with comprehensive and reliable auxiliary diagnostic information, helps doctors complete their work quickly, and relieves the pain points of inadequate basic ophthalmic medical resources.
Cloud Service:
It adopts a cloud platform architecture and can be browsed anytime and anywhere on multiple terminals such as computers, tablets, and mobile phones after a single collection, providing platform support for remote grading diagnosis and treatment.
Fully automatic AI-assisted BV1000 OCT
Compared with the MIAS released in 2018, Big Vision’s products have evolved from algorithm software to a combination of software and hardware, which is a route choice made by Big Vision Medical according to market demand. The base of eye disease patients in China is huge. With the aging of the population, age-related, metabolic, and highly myopic fundus diseases have become the leading irreversible causes of blindness, accounting for 54.7% of all blind patients.
OCT is an authoritative examination device for clinical diagnosis and treatment of fundus diseases, but the traditional OCT operating steps are complex and film reading relies on high-level professional doctors, which limits the popularization and application of OCT at the grassroots
level. Empowering it with advanced ophthalmic AI technology is an effective way to solve the shortage of ophthalmic medical resources at the grassroots level in China.
Big Vision Medical’s self-developed new generation of fully automatic AI-assisted OCT BV1000 was launched on the market in 2020 and has now been applied in nearly a hundred hospitals; in 2022, the landing of BV1000 in hospitals is accelerating, and its sales revenue has exceeded tens of millions of yuan.
Innovation-driven development, technology leading the future. Looking to the future, as a pioneer in ophthalmic imaging AI analysis and diagnosis in China, Big Vision Medical Technology will continue to uphold the corporate spirit of “dream, passion, and pragmatism”, forge ahead, empower ophthalmic diagnosis and treatment with artificial intelligence, and strive to build itself into a global leader in ophthalmic AI.
No comments yet.